china semaglutide patent expiry and new GLP‑1 entries intensify global obesity drug fight With the patent expiration of

doi:10.1074/jbc.273.51.33905 58

There is no trial confirming this works as well as the full dose of both - it is a community pattern

Others note the potential for retatrutide, if cleared, to make its way onto obesity treatment guidelines, particularly if studies identify comparable or higher effects

The volume loss data (well-documented) The 2025 Vanderbilt study by Sharma and colleagues ( Otolaryngology-Head and Neck Surgery 173(2):360-366, PMID 40407186) is the strongest objective measurement of GLP-1 facial volume loss to date

Patients should gradually increase their dose from the starting 1.5mg a day all the way up to 25mg a day, which may take 90 days or longer to do

Additional compounds worth considering Beyond the seven primary peptides discussed above, several other compounds deserve mention in the context of menopausal metabolic support